Pascal van Wijnen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pascal van Wijnen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Philipp Klemm
Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Bad Nauheim, Germany
7 shared publications - Nils Schulz
Justus Liebig University Giessen, Campus Kerckhoff, Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Bad Nauheim, Germany
5 shared publications - Tim Wilhelmi
Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Bad Nauheim, Germany
5 shared publications - Ulf Müller-Ladner
Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Bad Nauheim, Germany
5 shared publications - Uwe Lange
Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Bad Nauheim, Germany
3 shared publications - Gunter Assmann
RUB-Universitätsklinikum Minden JWK, Klinik für Rheumatologie und klinische Immunologie, Ruhr University Bochum, Minden, Deutschland
2 shared publications
Latest Publications
- Open Access
- 18 April 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (2) , 100171
A hip that breaks the scale
- 18 April 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (2) , 100171
Open AccessA hip that breaks the scale
- Open Access
- 13 April 2026
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 43 (1) , 2653012
Effects of locally applied water-filtered infrared a irradiation adjunctive to iloprost and carbon dioxide hand baths in patients with systemic sclerosis and severe Raynaud’s phenomenon – a randomized controlled trial
Up to 95% of patients with systemic sclerosis (SSc) experience Raynaud’s phenomenon (RP), characterized by recurrent digital vasospasm triggered by cold or stress, leading to ischemia, pain, and, i...
- 13 April 2026
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 43 (1) , 2653012
Open AccessEffects of locally applied water-filtered infrared a irradiation adjunctive to iloprost and carbon dioxide hand baths in patients with systemic sclerosis and severe Raynaud’s phenomenon – a randomized controlled trial
Up to 95% of patients with systemic sclerosis (SSc) experience Raynaud’s phenomenon (RP), characterized by recurrent digital vasospasm triggered by cold or stress, leading to ischemia, pain, and, i...
- Open Access
- 18 December 2025
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 85 (2) , 114-125
Behandlung der adulten chronisch nicht-bakteriellen Osteitis in Deutschland
Zusammenfassung: Die nicht-interventionelle Beobachtungsstudie analysierte mit einem retro- und prospektiven Design die Behandlungsrealität von 114 Patienten mit adulter chronisch nicht-bakterieller Osteitis (CNO) an drei deutschen universitären Zentren über den Zeitraum 1985 bis 2025. Primäres Ziel war der Abgleich der Therapieverläufe in Deutschland mit den im Jahr 2024 publizierten internationalen Konsensempfehlungen. Die Empfehlungen favorisieren nichtsteroidale Antirheumatika (NSAR) und Coxibe in der ersten und Tumornekrosefaktor-Inhibitoren (TNFi) oder Bisphosphonate in der zweiten Linie der Therapie. Die Ergebnisse zeigen, dass zwar 61 % zuerst NSAR erhielten, aber nur 20 % in der empfohlenen Ausdosierung der Erstlinientherapie. Hingegen erhielten 46 % der adulten CNO-Patienten in der Erstlinie eine konventionell-synthetische Basistherapie (csDMARDs). Diese wird aufgrund der reduzierten Wirksamkeit aktuell nur in Einzelfällen empfohlen, wenn eine Überlappung der adulten CNO mit axialer Spondylarthritis (axSpA) oder Psoriasisarthritis (PsA) vorliegt. Unsere Daten zeigen, dass eine Überlappung in insgesamt 70 % der adulten CNO-Fälle auftrat. In der zweiten Linie der Therapie kamen wie empfohlen TNFi zum Einsatz, während die alternativ hierzu empfohlenen Bisphosphonate nur bei einem Patienten eingesetzt wurden. Das beobachtete Therapieansprechen betrug, gemessen an der Rate der Therapieabbrüche, innerhalb von 12 Monaten maximal 53 %. Die vorliegenden Daten unterstreichen die Relevanz der aktuellen Empfehlungen zur Vereinheitlichung der Terminologie und zur Optimierung der therapeutischen Versorgung von Patienten mit adulter CNO. Ungelöst bleiben dabei die fehlende ICD-10-Codierung und Zulassung der durch die Konsensempfehlungen vorgeschlagenen Therapie für den deutschen Raum.
- 18 December 2025
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 85 (2) , 114-125
Open AccessBehandlung der adulten chronisch nicht-bakteriellen Osteitis in Deutschland
Zusammenfassung: Die nicht-interventionelle Beobachtungsstudie analysierte mit einem retro- und prospektiven Design die Behandlungsrealität von 114 Patienten mit adulter chronisch nicht-bakterieller Osteitis (CNO) an drei deutschen universitären Zentren über den Zeitraum 1985 bis 2025. Primäres Ziel war der Abgleich der Therapieverläufe in Deutschland mit den im Jahr 2024 publizierten internationalen Konsensempfehlungen. Die Empfehlungen favorisieren nichtsteroidale Antirheumatika (NSAR) und Coxibe in der ersten und Tumornekrosefaktor-Inhibitoren (TNFi) oder Bisphosphonate in der zweiten Linie der Therapie. Die Ergebnisse zeigen, dass zwar 61 % zuerst NSAR erhielten, aber nur 20 % in der empfohlenen Ausdosierung der Erstlinientherapie. Hingegen erhielten 46 % der adulten CNO-Patienten in der Erstlinie eine konventionell-synthetische Basistherapie (csDMARDs). Diese wird aufgrund der reduzierten Wirksamkeit aktuell nur in Einzelfällen empfohlen, wenn eine Überlappung der adulten CNO mit axialer Spondylarthritis (axSpA) oder Psoriasisarthritis (PsA) vorliegt. Unsere Daten zeigen, dass eine Überlappung in insgesamt 70 % der adulten CNO-Fälle auftrat. In der zweiten Linie der Therapie kamen wie empfohlen TNFi zum Einsatz, während die alternativ hierzu empfohlenen Bisphosphonate nur bei einem Patienten eingesetzt wurden. Das beobachtete Therapieansprechen betrug, gemessen an der Rate der Therapieabbrüche, innerhalb von 12 Monaten maximal 53 %. Die vorliegenden Daten unterstreichen die Relevanz der aktuellen Empfehlungen zur Vereinheitlichung der Terminologie und zur Optimierung der therapeutischen Versorgung von Patienten mit adulter CNO. Ungelöst bleiben dabei die fehlende ICD-10-Codierung und Zulassung der durch die Konsensempfehlungen vorgeschlagenen Therapie für den deutschen Raum.
- Open Access
- 5 December 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 148
Correction to: Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study
- 5 December 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 148
Open AccessCorrection to: Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study
- Open Access
- 22 July 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-10
Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study
Rheumatoid arthritis (RA) is associated with systemic bone loss and thus an established risk factor for osteoporosis. Janus kinase inhibitors (JAKi) have shown osteo-protective effects. However, clinical data on the effects of baricitinib on bone mineral density (BMD) remain limited. Therefore, we investigated the effects of a 1-year treatment with baricitinib on BMD in RA patients. Patients with active RA beginning treatment with baricitinib were included. BMD was measured at the lumbar spine and femoral neck using Dual-Energy X-Ray Absorptiometry (DXA). Disease activity was assessed using DAS28-CRP and cDAI. The primary endpoint was the change in BMD after 12 months. Secondary endpoints evaluated changes in disease activity, prednisolone dose and alkaline phosphatase (AP) levels and its relation to BMD. A total of 46 RA patients were recruited, of whom 26 completed the study. Overall, BMD remained stable. Non-responders to baricitinib (based on DAS28-CRP) showed a significant decline in spine BMD (− 2.12%, p = 0.039), while responders showed stable BMD. The between-group difference in spine BMD ( p = 0.008) and T-score ( p = 0.012) was significant. Demographic and clinical characteristics did not differ significantly between groups. Disease activity (DAS28-CRP: p = 0.003; cDAI: p = 0.007), prednisolone dose ( p = 0.006), and AP levels ( p = 0.03) all improved significantly. Under baricitinib, BMD loss appeared stabilized in RA patients. Non-responders to baricitinib experienced a significant loss of BMD with a significant difference to responders raising the question if seen effects are achieved by controlling disease activity or if there is an additional explicit JAKi effect on bone metabolism. Trial registration number: DRKS00020780, date: 13.3.2020.
- 22 July 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-10
Open AccessBone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study
Rheumatoid arthritis (RA) is associated with systemic bone loss and thus an established risk factor for osteoporosis. Janus kinase inhibitors (JAKi) have shown osteo-protective effects. However, clinical data on the effects of baricitinib on bone mineral density (BMD) remain limited. Therefore, we investigated the effects of a 1-year treatment with baricitinib on BMD in RA patients. Patients with active RA beginning treatment with baricitinib were included. BMD was measured at the lumbar spine and femoral neck using Dual-Energy X-Ray Absorptiometry (DXA). Disease activity was assessed using DAS28-CRP and cDAI. The primary endpoint was the change in BMD after 12 months. Secondary endpoints evaluated changes in disease activity, prednisolone dose and alkaline phosphatase (AP) levels and its relation to BMD. A total of 46 RA patients were recruited, of whom 26 completed the study. Overall, BMD remained stable. Non-responders to baricitinib (based on DAS28-CRP) showed a significant decline in spine BMD (− 2.12%, p = 0.039), while responders showed stable BMD. The between-group difference in spine BMD ( p = 0.008) and T-score ( p = 0.012) was significant. Demographic and clinical characteristics did not differ significantly between groups. Disease activity (DAS28-CRP: p = 0.003; cDAI: p = 0.007), prednisolone dose ( p = 0.006), and AP levels ( p = 0.03) all improved significantly. Under baricitinib, BMD loss appeared stabilized in RA patients. Non-responders to baricitinib experienced a significant loss of BMD with a significant difference to responders raising the question if seen effects are achieved by controlling disease activity or if there is an additional explicit JAKi effect on bone metabolism. Trial registration number: DRKS00020780, date: 13.3.2020.
- 21 July 2025
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 84 (6) , 419-424
Adulte chronische nichtbakterielle Osteitis
Pt nanoparticles supported onto carbon black were synthesized via non-isothermal decomposition of platinum acetylacetonate. The Pt loading of Pt/C exhibited variation within the range of 10-25%. Based on the refinement of X-ray patterns by the Rietveld method, it was shown that the average size of Pt nanocrystallites in the range of 1.4-2.0 nm increases with increasing Pt loading. The paper presents a synthesis mechanism describing the observed dependence. In addition, it was found that for the synthesized Pt nanoparticles, the unit cell parameter increases as the average size of Pt nanoparticles decreases. Such an effect has not been observed for platinum nanoparticles before. The reason for the observed increase in the unit cell perimeter of Pt nanoparticles is the dominance of the vacancy mechanism over the surface relaxation mechanism. Finally, the paper presents for the first time a method for refining X-ray patterns of Pt/C materials taking into account the contribution of the carbon support, which allows for an accurate analysis of the treatment of X-ray patterns of Pt/C materials with a low content of the metallic component.
- 21 July 2025
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 84 (6) , 419-424
Adulte chronische nichtbakterielle Osteitis
Pt nanoparticles supported onto carbon black were synthesized via non-isothermal decomposition of platinum acetylacetonate. The Pt loading of Pt/C exhibited variation within the range of 10-25%. Based on the refinement of X-ray patterns by the Rietveld method, it was shown that the average size of Pt nanocrystallites in the range of 1.4-2.0 nm increases with increasing Pt loading. The paper presents a synthesis mechanism describing the observed dependence. In addition, it was found that for the synthesized Pt nanoparticles, the unit cell parameter increases as the average size of Pt nanoparticles decreases. Such an effect has not been observed for platinum nanoparticles before. The reason for the observed increase in the unit cell perimeter of Pt nanoparticles is the dominance of the vacancy mechanism over the surface relaxation mechanism. Finally, the paper presents for the first time a method for refining X-ray patterns of Pt/C materials taking into account the contribution of the carbon support, which allows for an accurate analysis of the treatment of X-ray patterns of Pt/C materials with a low content of the metallic component.
- Open Access
- 26 June 2025
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 1 (3) , 81-88
Effectiveness and safety of antiresorptive drugs in patients with systemic sclerosis—a retrospective monocentric study
- 26 June 2025
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 1 (3) , 81-88
Open AccessEffectiveness and safety of antiresorptive drugs in patients with systemic sclerosis—a retrospective monocentric study